title: Newly proposed therapy-related myelodysplastic syndrome prognostic score predicts significant differences in overall survival and leukemia-free survival in patients treated with azacitidine.
authors.forename: Massimo
authors.initials: M
authors.lastname: Breccia
authors.forename: Luana
authors.initials: L
authors.lastname: Fianchi
authors.forename: Monia
authors.initials: M
authors.lastname: Lunghi
authors.forename: Gianluca
authors.initials: G
authors.lastname: Gaidano
authors.forename: Alessandro
authors.initials: A
authors.lastname: Levis
authors.forename: Carlo
authors.initials: C
authors.lastname: Finelli
authors.forename: Valeria
authors.initials: V
authors.lastname: Santini
authors.forename: Pellegrino
authors.initials: P
authors.lastname: Musto
authors.forename: Giovanna
authors.initials: G
authors.lastname: Mansueto
authors.forename: Esther N
authors.initials: EN
authors.lastname: Oliva
authors.forename: Pietro
authors.initials: P
authors.lastname: Leoni
authors.forename: Maria Antonietta Aloe
authors.initials: MA
authors.lastname: Spiriti
authors.forename: Stefan
authors.initials: S
authors.lastname: Hohaus
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Leone
authors.forename: Giuliana
authors.initials: G
authors.lastname: Alimena
authors.forename: Maria Teresa
authors.initials: MT
authors.lastname: Voso
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D001374:Azacitidine / Q000627:therapeutic use*; D006801:Humans; D009190:Myelodysplastic Syndromes / Q000139:chemically induced / Q000188:drug therapy* / Q000401:mortality*; D016609:Neoplasms, Second Primary / Q000139:chemically induced / Q000188:drug therapy* / Q000401:mortality*; D016896:Treatment Outcome
chemical_list: D000964:Antimetabolites, Antineoplastic; D001374:Azacitidine